Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19

Shots:

• The P-III study evaluating BNT162b2 (COVID-19 Vaccine) vs PBO in >44,000 participants age ≥16 yrs with 927 confirmed symptomatic cases of COVID-19
• The results demonstrated that BNT162b2 is 91.3% effective against COVID-19, follow-up time of at least 6 mos after the 2nd dose, 100% effective in preventing severe disease by CDC, 95.3% effective against severe COVID-19 by US FDA, effective against B.1.351 variant, safe and tolerable
• The companies plan to share the results with worldwide regulatory agencies

Click here to­ read full press release/ article | Ref: Pfizer | Image: Bloomberg Quint